Need help finding what you are looking for?
Contact Us
PUBLISHER: Grand View Research | PRODUCT CODE: 1633800
PUBLISHER: Grand View Research | PRODUCT CODE: 1633800
U.S. Hospital And Nursing Home Probiotics Market Size, Share & Trends Analysis Report By Channel (Hospital, Nursing Home), By Function (Gut Health, Immunity, Wellness, Others), And Segment Forecasts, 2025 - 2030
PUBLISHED:
PAGES: 60 Pages
DELIVERY TIME: 2-10 business days
SELECT AN OPTION
U.S. Hospital & Nursing Home Probiotics Market Growth & Trends:
The U.S. hospital and nursing home probiotics market size is estimated to reach USD 305.2 million by 2030, expanding at a CAGR of 8.7% from 2025 to 2030, according to a new report by Grand View Research, Inc. Growth in use of probiotics in healthcare institutions has created various new applications for the product, which is contributing toward development of this market.
Rising demand for natural and healthy products is encouraging manufacturers to include probiotics in their products, which is projected to propel demand in the coming years. Manufacturers are also currently involved in overall market development by creating awareness about the advantages of probiotics. For this purpose, they prefer a collaborative approach by entering into long-term partnerships with probiotic strain suppliers.
In U.S., the ratio of community hospital capacity per 1,000 residents was 2.5 beds per individual in 2014, while the average duration of stay was 5.5 days per hospital stay. Hospital care has witnessed substantial changes over the past four decades. This transformation can be attributed to several factors such as reform in payment systems, modification in practice patterns, shift in consumer preferences, and technological advancements in medical care.
In U.S., rural residents are facing more health problems than urban citizens. Some of the major factors behind poorer healthcare conditions in rural areas in the country are social and cultural differences, economic factors, and educational shortcomings. However, the rural segment is projected to witness the fastest growth rate over coming years owing to presence of various untapped markets, which is attracting healthcare institutions to open or expand their operational and distribution facilities.
U.S. Hospital & Nursing Home Probiotics Market Report Highlights:
- The U.S. hospital & nursing home probiotic market is projected to reach USD 305.2 million by 2025 at an estimated CAGR of 8.7% from 2025 to 2030
- In October 2024, Probi announced the launch of the 'Metabolic Health by Probi' probiotic concept at the SupplySide West 2024 event held in Las Vegas. The product supports metabolic health, weight management, and cardiovascular health by targeting the key markers of metabolic syndrome, which is a condition linked to an increased risk of diabetes and cardiovascular diseases. The solution uses two proprietary strains, the Lactiplantibacillus plantarum 299v (LP299V) and the Lacticaseibacillus paracasei 8700:2, to address these issues while also promoting gut health.
- The share of the rural population reporting fair to poor physical health is nearly one and a half times the percentage of urban residents
- Lucrative opportunities in U.S. are bound to attract new entrants. However, massive investments required for carrying out R&D operations is a cause for concern for new entrants
- Some of the key companies present in the market are Bio-K Plus International Inc.; Probi AB; Dietary Pros, Inc.; i-Health, Inc.; and Probium LLC.
Product Code: GVR-2-68038-119-1
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.2. Market Definition
- 1.3. Information Procurement
- 1.3.1. Purchased Database
- 1.3.2. GVR's Internal Database
- 1.3.3. Secondary Products & Third-Party Perspectives
- 1.3.4. Primary Research
- 1.4. Information Analysis
- 1.4.1. Data Analysis Models
- 1.5. Market Formulation & Data Visualization
- 1.6. Data Validation & Publishing
Chapter 2. Executive Summary
- 2.1. Market Snapshot
- 2.2. Segment Snapshot
- 2.3. Competitive Landscape Snapshot
Chapter 3. U.S. Hospital and Nursing Home Probiotics Market Variables, Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent Market Outlook
- 3.1.2. Related Market Outlook
- 3.2. Industry Value Chain Analysis
- 3.2.1. Profit Margin Analysis (Industry-level)
- 3.3. Market Dynamics
- 3.3.1. Market Driver Analysis
- 3.3.2. Market Restraint Analysis
- 3.3.3. Market Opportunities
- 3.3.4. Market Challenges
- 3.4. Industry Analysis Tools
- 3.4.1. Porter's Five Forces Analysis
- 3.5. Market Entry Strategies
Chapter 4. Consumer Behavior Analysis
- 4.1. Demographic Analysis
- 4.2. Consumer Trends and Preferences
- 4.3. Factors Affecting Buying Decision
- 4.4. Consumer Product Adoption
- 4.5. Observations & Recommendations
Chapter 5. U.S. Hospital and Nursing Home Probiotics Market: Channel Estimates & Trend Analysis
- 5.1. U.S. Hospital and Nursing Home Probiotics Market, By Channel: Key Takeaways
- 5.2. Channel Movement Analysis & Market Share, 2024 & 2030
- 5.3. Market Estimates & Forecasts, By Channel, 2018 - 2030 (USD Million)
- 5.3.1. Hospital
- 5.3.1.1. Market estimates and forecast, 2018 - 2030 (USD Million)
- 5.3.2. Nursing Home
- 5.3.2.1. Market estimates and forecast, 2018 - 2030 (USD Million)
- 5.3.1. Hospital
Chapter 6. U.S. Hospital and Nursing Home Probiotics Market: Function Estimates & Trend Analysis
- 6.1. U.S. Hospital and Nursing Home Probiotics Market, By Function: Key Takeaways
- 6.2. Function Movement Analysis & Market Share, 2024 & 2030
- 6.3. Market Estimates & Forecasts, by Function, 2018 - 2030 (USD Million)
- 6.3.1. Gut Health
- 6.3.1.1. Market estimates and forecast, 2018 - 2030 (USD Million)
- 6.3.2. Immunity
- 6.3.2.1. Market estimates and forecast, 2018 - 2030 (USD Million)
- 6.3.3. Wellness
- 6.3.3.1. Market estimates and forecast, 2018 - 2030 (USD Million)
- 6.3.4. Others
- 6.3.4.1. Market estimates and forecast, 2018 - 2030 (USD Million)
- 6.3.1. Gut Health
Chapter 7. U.S. Hospital and Nursing Home Probiotics Market: Competitive Analysis
- 7.1. Recent developments & impact analysis, by key market participants
- 7.2. Company Categorization
- 7.3. Participant's Overview
- 7.4. Financial Performance
- 7.5. Product Benchmarking
- 7.6. Company Heat Map Analysis
- 7.7. Strategy Mapping
- 7.8. Company Profiles
- 7.8.1. Bio-K+, a Kerry company
- 7.8.1.1. Company Overview
- 7.8.1.2. Financial Performance
- 7.8.1.3. Product Portfolios
- 7.8.1.4. Strategic Initiatives
- 7.8.2. American Lifeline Inc.
- 7.8.2.1. Company Overview
- 7.8.2.2. Financial Performance
- 7.8.2.3. Product Portfolios
- 7.8.2.4. Strategic Initiatives
- 7.8.3. Rising Pharmaceuticals
- 7.8.3.1. Company Overview
- 7.8.3.2. Financial Performance
- 7.8.3.3. Product Portfolios
- 7.8.3.4. Strategic Initiatives
- 7.8.4. BD
- 7.8.4.1. Company Overview
- 7.8.4.2. Financial Performance
- 7.8.4.3. Product Portfolios
- 7.8.4.4. Strategic Initiatives
- 7.8.5. Dietary Pros, Inc.
- 7.8.5.1. Company Overview
- 7.8.5.2. Financial Performance
- 7.8.5.3. Product Portfolios
- 7.8.5.4. Strategic Initiatives
- 7.8.6. Dr. Joseph Mercola
- 7.8.6.1. Company Overview
- 7.8.6.2. Financial Performance
- 7.8.6.3. Product Portfolios
- 7.8.6.4. Strategic Initiatives
- 7.8.7. i-Health, Inc.
- 7.8.7.1. Company Overview
- 7.8.7.2. Financial Performance
- 7.8.7.3. Product Portfolios
- 7.8.7.4. Strategic Initiatives
- 7.8.8. Probi
- 7.8.8.1. Company Overview
- 7.8.8.2. Financial Performance
- 7.8.8.3. Product Portfolios
- 7.8.8.4. Strategic Initiatives
- 7.8.9. Lallemand Inc.
- 7.8.9.1. Company Overview
- 7.8.9.2. Financial Performance
- 7.8.9.3. Product Portfolios
- 7.8.9.4. Strategic Initiatives
- 7.8.10. Chr. Hansen A/S, part of Novonesis
- 7.8.10.1. Company Overview
- 7.8.10.2. Financial Performance
- 7.8.10.3. Product Portfolios
- 7.8.10.4. Strategic Initiatives
- 7.8.11. Biocodex
- 7.8.11.1. Company Overview
- 7.8.11.2. Financial Performance
- 7.8.11.3. Product Portfolios
- 7.8.11.4. Strategic Initiatives
- 7.8.12. Probiotical S.p.A.
- 7.8.12.1. Company Overview
- 7.8.12.2. Financial Performance
- 7.8.12.3. Product Portfolios
- 7.8.12.4. Strategic Initiatives
- 7.8.13. Protexin
- 7.8.13.1. Company Overview
- 7.8.13.2. Financial Performance
- 7.8.13.3. Product Portfolios
- 7.8.13.4. Strategic Initiatives
- 7.8.1. Bio-K+, a Kerry company
Product Code: GVR-2-68038-119-1
List of Tables
- Table 1 U.S. hospital and nursing home probiotics market: Key market driver analysis
- Table 2 U.S. hospital and nursing home probiotics market: Key market restraint analysis
- Table 3 U.S. hospital and nursing home probiotics market estimates & forecast, by channel (USD Million)
- Table 4 U.S. hospital and nursing home probiotics market estimates & forecast, by function (USD Million)
- Table 5 U.S. hospital probiotics market estimates & forecast, by number of beds (USD Million)
- Table 6 U.S. hospital probiotics market estimates & forecast, by payer (USD Million)
- Table 7 U.S. hospital probiotics market estimates & forecast, by location (USD Million)
- Table 8 U.S. nursing home probiotics market estimates & forecast, by number of beds (USD Million)
- Table 9 U.S. nursing home probiotics market estimates & forecast, by payer (USD Million)
- Table 10 U.S. nursing home probiotics market estimates & forecast, by ownership (USD Million)
- Table 11 Recent developments & impact analysis, by key market participants
- Table 12 Company heat map analysis, 2024
- Table 13 Companies implementing key strategies
List of Figures
- Fig. 1 U.S. hospital and nursing home probiotics market segmentation
- Fig. 2 Information procurement
- Fig. 3 Primary research pattern
- Fig. 4 Primary research approaches
- Fig. 5 Primary research process
- Fig. 6 Market snapshot
- Fig. 7 Segment snapshot
- Fig. 8 Regional snapshot
- Fig. 9 Competitive landscape snapshot
- Fig. 10 Global parent industry and U.S. hospital and nursing home probiotics market size (USD Million)
- Fig. 11 U.S. hospital and nursing home probiotics market size, 2018 to 2030 (USD Million)
- Fig. 12 U.S. hospital and nursing home probiotics market: Penetration & growth prospect mapping
- Fig. 13 U.S. hospital and nursing home probiotics market: Value chain analysis
- Fig. 14 U.S. hospital and nursing home probiotics market: Dynamics
- Fig. 15 U.S. hospital and nursing home probiotics market: Porter's five forces analysis
- Fig. 16 U.S. hospital and nursing home probiotics market estimates & forecast, by channel (USD Million)
- Fig. 17 Hospitals market estimates & forecasts, 2018 - 2030 (USD Million)
- Fig. 18 Nursing homes market estimates & forecasts, 2018 - 2030 (USD Million)
- Fig. 19 U.S. hospital and nursing home probiotics market estimates & forecast, by function (USD Million)
- Fig. 20 Gut health market estimates & forecasts, 2018 - 2030 (USD Million)
- Fig. 21 Immunity market estimates & forecasts, 2018 - 2030 (USD Million)
- Fig. 22 Wellness market estimates & forecasts, 2018 - 2030 (USD Million)
- Fig. 23 Other functions market estimates & forecasts, 2018 - 2030 (USD Million)
- Fig. 24 Key company categorization
- Fig. 25 Strategic framework of U.S. hospital and nursing home probiotics
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.